Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment
The advent of more effective treatment combinations for metastatic hormone-sensitive
prostate cancer (mHSPC) has been built on successes in therapy development for …
prostate cancer (mHSPC) has been built on successes in therapy development for …
De novo metastatic prostate cancer: Are we moving toward a personalized treatment?
C Piombino, M Oltrecolli, E Tonni, M Pirola, R Matranga… - Cancers, 2023 - mdpi.com
Simple Summary De novo metastatic hormone-sensitive prostate cancer usually has a
dismal prognosis, which has slightly improved in recent years thanks to the introduction of …
dismal prognosis, which has slightly improved in recent years thanks to the introduction of …
Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy
AV Serritella, M Hussain - Current Treatment Options in Oncology, 2024 - Springer
Opinion Statement Treatment for metastatic hormone–sensitive prostate cancer has
undergone significant evolution in recent years, leading to substantial improvements in …
undergone significant evolution in recent years, leading to substantial improvements in …
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
The landscape of advanced prostate cancer treatment has evolved tremendously in past
decades. The treatment paradigm has shifted from androgen deprivation therapy (ADT) …
decades. The treatment paradigm has shifted from androgen deprivation therapy (ADT) …
[HTML][HTML] Utility and Clinical Application of Circulating Tumor DNA (ctDNA) in Advanced Prostate Cancer
The treatment landscape for metastatic prostate cancer has undergone significant changes
in recent years. The availability of next-generation imaging techniques and the emergence …
in recent years. The availability of next-generation imaging techniques and the emergence …
[HTML][HTML] Liquid biopsy to personalize treatment for metastatic prostate cancer
M Lopez-Valcarcel, F Lopez-Campos… - American Journal of …, 2024 - ncbi.nlm.nih.gov
Liquid biopsy is an innovative approach that provides a more complete understanding of
treatment response and prognosis in monitoring metastatic prostate cancer. It complements …
treatment response and prognosis in monitoring metastatic prostate cancer. It complements …
The Musculo-Skeletal Effects of Systemic Anti-Cancer Therapies Combined with Standard Androgen Deprivation in High Risk Localised and Metastatic Hormone …
C Jones - 2024 - search.proquest.com
Introduction: Androgen deprivation therapy (ADT) is the mainstay systemic treatment for men
with high-risk non-metastaic (M0) and metastatic (M1) prostate cancer leading to bone …
with high-risk non-metastaic (M0) and metastatic (M1) prostate cancer leading to bone …